Kemia, Inc. Announces Completion Of Phase I Trials For Oral Anti-Inflammatory Drug; KC706, A p38 MAP Kinase Inhibitor, Targets Inflammatory Conditions Including Arthritis, Psoriasis, And Cardiovascular Disease
8/23/2006 11:10:24 AM
More...
|
Kemia, Inc. Closes Series C Financing
8/23/2006 11:05:55 AM
More...
|
Kemia, Inc. Announces Initiation Of Phase I Trials For Oral Anti-Inflammatory
10/19/2005 5:13:19 PM
More...
|
Kemia, Inc. Announces Appointment Of Chief Medical Officer And VP Of Business Development; Management Changes Reflect Kemia's Commitment To Advance Compounds Into The Clinic
10/19/2005 5:12:01 PM
More...
|
Kemia Raises $33.5 Million In Series B Financing Led By JPMorgan Partners
10/19/2005 5:10:36 PM
More...
|